<unk>  is designed to interfere with the triggering of the body's inflammatory response through the suppression of certain cytokines. Specifically, it blocks interleukin IL-12 and IL-23 which help activate certain T-cells. It binds to the p-40 subunit of both IL-12 and IL-23 so that they subsequently cannot bind to their receptors.
Ustekinumab
Olaratumab
Evolocumab
Emapalumab
Tralokinumab
Alirocumab
Evinacumab
Anifrolumab